SGX942

DRUG2 trials

Sponsors

Soligenix

Conditions

Oral MucositisSquamous Cell Carcinoma of the Oral Cavity and Oropharynx

Phase 2

A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer

CompletedNCT02013050

SoligenixOral Mucositis

Start: 2013-12-31End: 2016-09-30Updated: 2017-08-28

Phase 3

DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer

CompletedNCT03237325

SoligenixOral Mucositis, Squamous Cell Carcinoma of the Oral Cavity and Oropharynx

Start: 2017-12-04End: 2021-06-24Updated: 2022-11-08